Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $1.2 million.

  • Pharma's Cash & Current Investments fell 2529.11% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 2529.11%. This contributed to the annual value of $405000.0 for FY2025, which is 6625.0% down from last year.
  • Latest data reveals that Pharma reported Cash & Current Investments of $1.2 million as of Q3 2025, which was down 2529.11% from $454000.0 recorded in Q2 2025.
  • Pharma's 5-year Cash & Current Investments high stood at $14.6 million for Q1 2021, and its period low was $405000.0 during Q1 2025.
  • Its 5-year average for Cash & Current Investments is $5.4 million, with a median of $3.2 million in 2023.
  • As far as peak fluctuations go, Pharma's Cash & Current Investments soared by 30232.48% in 2021, and later plummeted by 7510.96% in 2025.
  • Over the past 5 years, Pharma's Cash & Current Investments (Quarter) stood at $11.9 million in 2021, then plummeted by 57.11% to $5.1 million in 2022, then tumbled by 73.09% to $1.4 million in 2023, then plummeted by 65.89% to $470000.0 in 2024, then skyrocketed by 145.74% to $1.2 million in 2025.
  • Its Cash & Current Investments stands at $1.2 million for Q3 2025, versus $454000.0 for Q2 2025 and $405000.0 for Q1 2025.